By Counterforce Health Team in Prolastin-C (alpha1-proteinase inhibitor) —

How to Get Prolastin-C Approved by UnitedHealthcare in Pennsylvania: Complete Prior Authorization and Appeal Guide

Answer Box: Getting Prolastin-C Approved by UnitedHealthcare in Pennsylvania

Prolastin-C requires prior authorization from UnitedHealthcare OptumRx for Pennsylvania patients. To get approved: (1) Gather genetic testing showing Pi*ZZ genotype, recent lung function tests (FEV1), and chest CT showing emphysema, (2) Submit PA via UHCprovider.com portal with ICD-10 codes E88.01 and J43.1, and (3) If denied, use Pennsylvania's new external review program—which overturns 50% of denials—within 4 months of your final denial letter.

First step today: Log into the UnitedHealthcare Provider Portal and check if Prolastin-C is covered under your specific plan's formulary.

Table of Contents

  1. What This Guide Covers
  2. Before You Start: Verify Your Coverage
  3. Gather Required Documentation
  4. Submit Your Prior Authorization Request
  5. Follow-Up and Tracking
  6. Typical Timelines in Pennsylvania
  7. If You Need More Information
  8. If You're Denied: Appeal Process
  9. Pennsylvania's External Review Advantage
  10. Renewal and Reauthorization
  11. Quick Reference Checklist

What This Guide Covers

This guide helps Pennsylvania patients and their healthcare providers navigate UnitedHealthcare's prior authorization process for Prolastin-C (alpha1-proteinase inhibitor). Whether you're dealing with a first-time request or appealing a denial, you'll find specific forms, timelines, and strategies that work in Pennsylvania's healthcare system.

Who this helps: Patients with severe alpha-1 antitrypsin deficiency, their families, pulmonologists, and specialty pharmacies working with UnitedHealthcare plans in Pennsylvania.

Before You Start: Verify Your Coverage

Check Your Plan Type

UnitedHealthcare covers Prolastin-C differently depending on your plan:

  • Commercial plans: Tier 3 coverage (highest copay) starting 2026
  • Medicare Advantage: Medical benefit coverage with 9% average denial rate
  • Pennsylvania Medicaid: Requires PA through OptumRx (effective March 2024)

Confirm Medical vs. Pharmacy Benefit

Prolastin-C is covered under the medical benefit, not pharmacy. This means:

  • Submit PA requests to UnitedHealthcare medical review, not OptumRx pharmacy
  • Coverage includes home infusion, infusion centers, and physician offices
  • Hospital outpatient administration requires additional justification
Note: If your PA gets routed to pharmacy benefits by mistake, request it be transferred to medical review to avoid delays.

Gather Required Documentation

Essential Clinical Evidence

Your pulmonologist needs these documents ready before submitting:

Genetic Testing:

  • Pi*ZZ genotype confirmation from CLIA-certified lab
  • Alpha-1 antitrypsin level <11 micromol/L

Lung Function Evidence:

  • Spirometry showing FEV1 30-65% predicted (within 6 months)
  • High-resolution chest CT documenting panlobular emphysema

Clinical History:

  • Smoking cessation documentation (≥6 months smoke-free)
  • Exacerbation history and hospitalizations
  • Previous treatments tried and failed

Required ICD-10 Codes

Include both codes for proper billing:

  • E88.01: Alpha-1 antitrypsin deficiency
  • J43.1: Panlobular emphysema

Submit Your Prior Authorization Request

Step-by-Step Submission Process

  1. Log into UHC Provider Portal at UHCprovider.com
  2. Select Prior Authorization tool from the main menu
  3. Enter patient information and diagnosis codes
  4. Upload all supporting documents in a single submission
  5. Include HCPCS code J0257 for alpha1-proteinase inhibitor
  6. Submit dosing plan: 60 mg/kg weekly infusion

Medical Necessity Letter Template

Your physician should include this language:

"Patient has alpha-1 antitrypsin deficiency with Pi*ZZ genotype confirmed by genetic testing. FEV1 is [X]% predicted with panlobular emphysema on HRCT. Prolastin-C is medically necessary per FDA labeling to raise AAT levels and reduce exacerbations. Alternative emphysema treatments do not address the underlying protein deficiency."

Contact Information for Help

  • OptumRx Help Desk: 800-711-4555
  • UnitedHealthcare Provider Services: 888-397-8129

Follow-Up and Tracking

When to Call

  • Day 3: Confirm PA was received and assigned
  • Day 7: Check status if no initial response
  • Day 10: Request expedited review if urgent

Sample Phone Script

"Hi, I'm calling to check the status of a prior authorization for Prolastin-C submitted [date] for patient [name]. The reference number is [if available]. Can you tell me if any additional information is needed?"

Document everything: Get representative names, reference numbers, and next steps in writing.

Typical Timelines in Pennsylvania

Review Type Timeline When It Applies
Standard PA 5-7 business days Most requests
Expedited PA ≤72 hours Life-threatening conditions
OptumRx PreCheck 29 seconds (if automated) Select medications
Tip: UnitedHealthcare's new PreCheck system may automatically approve some PAs. Check if Prolastin-C qualifies for your specific plan.

If You Need More Information

Common Information Requests

"Need more clinical justification":

  • Add ATS/ERS guideline citations
  • Include recent exacerbation documentation
  • Provide quality of life assessments

"Step therapy not documented":

  • Show trials of Aralast NP, Zemaira, or Glassia
  • Document contraindications or failures
  • Request step therapy exception if appropriate

If You're Denied: Appeal Process

UnitedHealthcare Internal Appeals

Level 1 Appeal (within 60 days):

  • Submit via provider portal or call 866-347-9507
  • Include updated clinical evidence
  • Request peer-to-peer review within 21 days if needed

Level 2 Appeal (if Level 1 denied):

  • Independent medical review
  • Same documentation requirements
  • Final internal decision

Common Denial Reasons and Solutions

Denial Reason Solution Documents Needed
Insufficient genetic evidence Submit complete lab report Pi*ZZ genotype from certified lab
Inadequate lung documentation Provide recent testing FEV1 + chest CT within 6 months
Step therapy not met Request exception Contraindication documentation
Not medically necessary Cite clinical guidelines ATS/ERS recommendations, FDA labeling

Pennsylvania's External Review Advantage

Pennsylvania launched its Independent External Review Program in January 2024, giving patients a powerful new tool to overturn denials.

Success Rates

  • 50.1% overturn rate in the first year
  • 259 successful appeals out of 517 total reviews
  • Binding decisions that insurers must follow

How to Request External Review

  1. Complete UnitedHealthcare's internal appeals first
  2. Receive Final Adverse Benefit Determination letter
  3. Submit request within 4 months at pa.gov/reviewmyclaim
  4. Include supporting documentation explaining medical necessity

Timeline for External Review

  • Standard review: Decision within 45 days
  • Expedited review: Decision within 72 hours (for urgent cases)
  • No cost to patients
Important: External review only applies to fully insured plans. Self-funded employer plans are excluded—check with your HR department.

Getting Help with External Review

  • Pennsylvania Insurance Department Consumer Services: 1-877-881-6388
  • Pennsylvania Health Law Project: Free assistance for complex cases
  • Pennie Consumer Hotline: For marketplace plan issues

At Counterforce Health, we help patients and clinicians turn insurance denials into successful appeals by creating targeted, evidence-backed letters that address each payer's specific requirements. Our platform identifies the exact denial reasons and drafts point-by-point rebuttals using the right clinical evidence and policy citations.

Renewal and Reauthorization

When to Reapply

Most Prolastin-C authorizations last 12 months. Start renewal process:

  • 90 days before expiration for standard review
  • 30 days before for expedited cases

Required Renewal Documentation

  • Updated pulmonary function tests
  • Treatment response documentation
  • Continued smoking cessation
  • Exacerbation frequency compared to baseline

Evidence of Treatment Benefit

Document positive response with:

  • Stable or improved FEV1
  • Reduced exacerbation frequency
  • Improved quality of life measures
  • No serious adverse events

Quick Reference Checklist

Before Submitting PA:

  • Genetic test results (Pi*ZZ genotype)
  • Recent spirometry (FEV1 30-65% predicted)
  • Chest CT showing panlobular emphysema
  • Smoking cessation documentation
  • Prior treatment history
  • ICD-10 codes: E88.01 and J43.1

During Review:

  • Track submission via UHC provider portal
  • Follow up on day 3 and day 7
  • Document all phone calls and reference numbers
  • Request expedited review if urgent

If Denied:

  • File Level 1 appeal within 60 days
  • Request peer-to-peer review within 21 days
  • Gather additional clinical evidence
  • Consider Pennsylvania external review after final denial

FAQ: Common Questions About Prolastin-C Coverage

Q: How long does UnitedHealthcare PA take in Pennsylvania? A: Standard prior authorization takes 5-7 business days. Expedited reviews for urgent cases are completed within 72 hours.

Q: What if Prolastin-C is non-formulary on my plan? A: Request a formulary exception with medical necessity documentation. UnitedHealthcare covers Prolastin-C as Tier 3 starting 2026.

Q: Can I get home infusion coverage? A: Yes, UnitedHealthcare prefers home infusion over hospital outpatient due to lower costs. Coverage includes home, infusion centers, and physician offices.

Q: Does step therapy apply if I failed other treatments outside Pennsylvania? A: Yes, document previous trials of Aralast NP, Zemaira, or Glassia with failure or contraindication details.

Q: What's the difference between Medicare Advantage and commercial coverage? A: Both use identical PA criteria, but Medicare Advantage has higher average denial rates (9% vs. commercial average). Both cover home infusion.

Q: How much does Prolastin-C cost without insurance? A: Annual treatment costs commonly exceed $80,000, with some studies showing average payer spending around $127,000 per year per patient.

When dealing with complex prior authorization requirements, having expert support can make the difference between approval and denial. Counterforce Health specializes in helping patients navigate these exact challenges by creating targeted appeals that address payer-specific criteria and include the right clinical evidence to support medical necessity.

Sources & Further Reading

Medical Disclaimer: This guide provides general information about insurance coverage processes and should not be considered medical advice. Always consult with your healthcare provider about treatment decisions and work with your insurance company directly for coverage determinations. Coverage policies and requirements may change; verify current information with UnitedHealthcare and Pennsylvania regulatory authorities.

Powered by Counterforce Health—AI that turns drug denials into evidence-based appeals patients and clinicians can submit today.